Category: 1408168-76-2

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1408168-76-2,Potassium trifluoro(2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl)borate,as a common compound, the synthetic route is as follows.

To a degassed solution of intermediate (10e) (1.35 g, 2.60 mmol) in toluene (15 ml_) and water (5 ml_) were added potassium 2-(tetrahydro-2/-/-pyran-2-yloxy)ethyltrifluoroborate (613 mg, 2.60 mmol), cesium carbonate (2.54 g, 7.79 mmol), RuPhos (121 mg, 0.26 mmol) and palladium(ll) acetate (29 mg, 0.13 mmol). The flask was sealed and the mixture was heated at 95C for 5h. The mixture was cooled to rt and water was added. The layers were separated. The aqueous layer was extracted with toluene. The combined organic layers were washed with brine, dried over Na2S04 and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (cyclohexane/ AcOEt 10/0 to 5/5) to provide intermediate (1 1 a) (1 .21 g, 2.12 mmol, 81%) as a yellow oil. MS m/z ([M+Na]+) 591., 1408168-76-2

The synthetic route of 1408168-76-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; MUTABILIS; BARBION, Julien; CARAVANO, Audrey; CHASSET, Sophie; CHEVREUIL, Francis; LE STRAT, Frederic; SIMON, Christophe; BRIAS, Julie; LEBEL, Remi; (80 pag.)WO2020/25543; (2020); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

1408168-76-2, Potassium trifluoro(2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl)borate is a Tetrahydropyrans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a 4 mL vial was added bis(di-tert-butyl(4-dimethylaminophenyl)phosphine) dichloro-palladium(II) (5.0 mg, 7.0 mumol), Cs2CO3 (137 mg, 0.422 mmol), tert-butyl 4-(5-chloro-6-methoxythieno[3,2-b]pyridin-2-yl)-4-oxobutanoate (50.0 mg, 0.141 mmol), and potassium trifluoro(2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl)borate (39.8 mg, 0.169 mmol). To the vial was added toluene (0.50 mL) and water (0.10 mL). The vial was degassed with N2 for 5 min. The mixture was heated to 100 C. for 18 h. Upon cooling to RT, the mixture was filtered through CELITE, and the CELITE was washed with EtOAc. The filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica gel chromatography (0?75% EtOAc gradient in Hex) to afford tert-butyl 4-(6-methoxy-5-(2-((tetrahydro-2H-pyran-2-yl)oxy) ethyl)thieno[3,2-b]pyridin-2-yl)-4-oxobutanoate. LCMS (C23H32NO6S) (ES, m/z): 450 [M+H]+. 1H NMR (500 MHz, CDCl3) delta 8.45 (s, 1H), 7.80 (s, 1H), 4.71 (s, 1H), 4.26-4.15 (m, 1H), 4.04 (s, 3H), 3.78 (t, J=8.3 Hz, 1H), 3.65-3.42 (m, 4H), 3.33 (t, J=6.3 Hz, 2H), 2.73 (t, J=6.3 Hz, 2H), 1.64-1.48 (m, 6H), 1.46 (s, 9H)., 1408168-76-2

As the paragraph descriping shows that 1408168-76-2 is playing an increasingly important role.

Reference£º
Patent; Merck Sharp & Dohme Corp.; Altman, Michael D.; Cash, Brandon D.; Childers, Matthew Lloyd; Cumming, Jared N.; DeMong, Duane E.; Haidle, Andrew Marc; Henderson, Timothy J.; Jewell, James P.; Larsen, Matthew A.; Lim, Jongwon; Lu, Min; Otte, Ryan D.; Trotter, Benjamin Wesley; US2019/300513; (2019); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics